AGE AND GENDER PECULIARITIES OF BLOOD LIPIDS IN URBAN RESIDENTS (CROSS-SECTIONAL STUDY RESULTS)

Aim. To analyze the results of measurements of the blood lipid spectrum of urban  residents of the European part of the Russian Federation.Material and methods. The results of single assessment of lipid profiles in 22,436 males and 35,100 females at the age from 13 to 94 years in 347 cities and towns  of the European part of the Russian Federation were analyzed. Lipid assays were performed by the Laboratory Service «HELIX» from 28 Jan 2015 to 19 Mar 2016.Statistical methods included descriptive statistics, the analysis of distributions of sample comparisons and the search of dependencies.Results. Results of 56,235 measurements of total cholesterol (TC), 22,641 – triglycerides (TG), 21,032 – high density lipoproteins cholesterol (HDL-C) and 22,441 – low density lipoprotein cholesterol (LDL-C) were analyzed. TC above 5.2 mmol/l was identified in 55.78% samples; the proportion of people with LDL-C level above 3.0 mmol/l was 62.95%. The level of TC was the highest at the age of 43 to 62 years in both men and women, while the peak in the increase in TC in men was approximately 10 years earlier, than  in women. In patients of older age groups, TC levels decreased and reached minimum values in men and women of senile age and long-livers. Low level of HDL-C was observed in 24.46% of the total number of samples in men and in 17.68% – in women. The monotonous increase in the average levels of HDL-C was revealed in men with aging. In women the HDL-C levels increased sharply from a minimum at the age of 13 years to a maximum at the age of 25 years with a slight monotonous decrease in the following age periods. However, even in the age older than 83 years levels of HDL-C remained high (1.49 mmol/l in average). The level of TG showed significant inter-age fluctuations, especially in men. The levels of TG above 1.7 mmol/l were recorded in 30.07% of all cases.Conclusion. Two-factor analysis of variance for all lipid parameters revealed a high statistical significance of gender and age

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

10.1111/ejh.13783European Journal of Haematology1093205-21